The pharmaceutical company GSK and Janssen decided to launch the EMIF consortium to for the first time bring distributed medical data together for the benefit of all cooperating parties. With this collaboration EMIF strives to find solutions for patients more quickly. It wants to build a platform that enables the efficient analysis of existing medical data. This is done by linking the different data sets and developing standardized access to them.

With the development of this platform EMIF focuses on two research areas: the origination of Alzheimer's disease and the metabolic complications of obesity. On the basis of existing experience in these two research fields, the consortium develops the basic platform that enables data collection, exchange and analysis for many disease areas in parallel.

.

The project receives European subsidies from the Innovative Medicines Initiative (IMI), Europe largest public/private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaboration projects in the healthcare sector to accelerate medical innovation.

The idea to set up this collaboration was developed at a Janssen Entrepreneurial Boot Camp, a training and coaching process that helps staff to transform innovative ideas for better healthcare into a sound business plan.